SBIR-STTR Award

Characterization of a Low Mutation Rate E. Coli in Extended Fermentation
Award last edited on: 1/31/18

Sponsored Program
SBIR
Awarding Agency
NIH : NIGMS
Total Award Amount
$2,716,452
Award Phase
2
Solicitation Topic Code
-----

Principal Investigator
Frederick R Blattner

Company Information

Scarab Genomics LLC

1202 Ann Street
Madison, WI 53713
   (608) 527-1624
   info@scarabgenomics.com
   www.scarabgenomics.com
Location: Multiple
Congr. District: 02
County: Dane

Phase I

Contract Number: 1R43GM105177-01
Start Date: 5/1/13    Completed: 10/31/13
Phase I year
2013
Phase I Amount
$297,922
This application aims to test a new Scarab E. coli strain, MDS42pdu, for commercial fermentation to produce biopharmaceuticals, amino acids and biofuels. It is designed for a very low rate of point mutations and Insertion Sequence transposition, especially in the stress conditions of recombinant protein production. We propose here to study the impact on a fundamental problem of large scale fermentation: Darwinian evolution of bacteria in the fermenter toward loss of productivity. Random mutations occurring in culture can produce cells freed from the burden of product formation and these have a selective advantage. Soon these overtake the culture and reduce or eliminate productivity. In short, cultures deteriorate. Selection of mutations can also undermine product purity. We would like to slow or eliminate this degradation of performance to improve stability, quality and efficiency of current fed batch methods and possibly, to support a more continuous fermentation protocol in the future. The proposed studies use periodic total genomic sequencing of extended cultures to compare ordinary production strains with the new low mutation strain to see if the period of culture productivity before degradation is extended, and whether we can identify the types of mutations involved in performance degradation. The two aims propose periodic whole genome sequencing of serially transferred cultures in shake flasks to quantify inexpensively the performance of the low mutation strain in a wide variety of cases, to be followed by more detailed study using continuous flow fermentation. We anticipate that control cultures using ordinary E. coli strains will become non productive considerably more quickly than MDS42pdu. If this anticipated result is found, we will determine the maximum number of generations before problems emerge in the new production sytem. If a greatly extended productive lifetime is achieved we will consider it a major milestone toward commercialization of our product for fed batch fermentation. Sequencing will also help determine whether additional mutational mechanisms may be active that could be beneficially inactivated in future work. An extremely long productive culture life will indicate the feasibility of a continuous fermentation process usig this strain.

Public Health Relevance Statement:


Public Health Relevance:
This proposal further develops Scarab Genomics' Clean Genome(R) E. coli to engineer a genetically stable strain for use in fermentation processes for biomanufacturing. Improved stability will provide higher quality bio- products and extended culturing will lead to higher yields from more efficient and cheaper production.

Project Terms:
Agreement; Amino Acids; Animal Feed; Antibodies; Bacteria; Biological Assay; Biological Products; Biomanufacturing; Businesses; Categories; Cell Line; Cells; Chemical Industry; Cloning; commercialization; Computers; Consult; Cytolysis; Data; design; Development; DNA; DNA Insertion Elements; Engineering; Escherichia coli; Evaluation; Evolution; experience; Fee-for-Service Plans; feeding; Fermentation; Flagella; flasks; Future; Gel; Generations; Genetic; Genome; genome sequencing; Genomic Segment; Genomics; Growth; Hormones; Immunoglobulin Fragments; improved; Infant formula; IS Elements; Lead; Legal patent; Length; Licensing; Life; Literature; Lymphokines; Mails; Marketing; Measures; meetings; Methods; Molecular Weight; Mutation; Organism; payment; Peptide Hydrolases; Peptides; Performance; Pharmacologic Substance; Phase; plasmid DNA; Plasmids; Point Mutation; Process; Production; Productivity; productivity loss; Prophages; Proteins; Protocols documentation; public health relevance; Publications; Reader; Recombinant Proteins; Recombinants; Research; Route; Sales; Sampling; Solutions; Staging; Stress; Swimming; Testing; Threonine; Time; web site; Work

Phase II

Contract Number: 2R44GM105177-02
Start Date: 5/1/13    Completed: 5/31/18
Phase II year
2016
(last award dollars: 2017)
Phase II Amount
$2,418,530

Scarab Genomics was founded to improve E coli as an industrial organism by genome engineering. These strains have stable genomes since all prophages, transposable and IS elements, and the error prone repair systems were removed. A recA- version has always been provided as an option. The goal of the Phase I project was to ascertain whether the changes already introduced are sufficient to realize extended or continuous fermentation. Data gathered in Phase I show that we have indeed supported that hypothesis. Data obtained using serial transfer with shake flasks met our criterion for production stability of 21 days, but only when the cultures were not induced. This suggested the use of a two tank system with seed and production tanks. To confirm this we performed actual fermentations using Scarab funds. The results show that stable production of a test protein, CRM197 can be extended at least 33 days with no loss of productivity. This is more than enough to justify a 10 fold lowering of the cost of production with continuous flow rather than fed batch procedures that have been used in for manufacturing in E. coli. Continuous cultures were also analyzed by DNA sequencing and this was able to detect contamination as well as mutations and rearrangements. This analysis also revealed that the Scarab strain competed well against contaminants in contrast to standard strains BL21. We are therefore proposing to take this system to the next level by developing a complete platform for continuous fermentation, called C-Flow. The FDA has recently encouraged adoption of continuous manufacturing in the pharmaceutical industry, and several large companies have recently signaled readiness to implement the change. Our aim is to attack the bottom line of E. coli fermentation by offering a simpler and cheaper process that will produce consistently higher quality bioproducts than fed batch fermentation. Our proposal is to fully characterize the C-flow system and work towards commercializing it by developing a prototype that fits in a standard 6 ft hood. One particularly useful feature will support optimization of fermentation parameters without the need to restart fermentation so the best possible performance can be quickly and inexpensively achieved by a user. Other products such as pDNA will be tested in the C-Flow system.

Public Health Relevance Statement:


Public Health Relevance:
Continuous fermentation will bring great benefits of improved drug manufacturing efficiency, as well as high and consistent drug product quality. The FDA is encouraging efforts to implement this technology in the pharmaceutical industry. Patients will have access to a wider range of quality medicines that are made more economically current technology permits.

NIH Spending Category:
Bioengineering; Biotechnology; Genetics; Immunization; Vaccine Related

Project Terms:
Address; Adopted; Adoption; Antibodies; Antitoxins; Attenuated; base; Biological; Biological Containment; Biological Products; commercialization; cost; cross reacting material 197; Cytoplasmic Protein; Data; design; Diphtheria Toxin; DNA Sequence Analysis; DNA Transposable Elements; Dose; Drug Industry; Engineering; Equipment; Escherichia coli; Experimental Designs; Failure; feeding; Fermentation; flasks; foot; Funding; Gelsolin; Genes; Genetic; Genetic Engineering; Genome; Genome engineering; genome sequencing; Genomics; Goals; improved; instrumentation; IS Elements; Medicine; meetings; Membrane Proteins; Methods; Microbial Biofilms; Modeling; Modification; Monitor; Mutation; nuclease; Organism; Patients; Peptide Hydrolases; Performance; Pharmaceutical Preparations; Pharmacologic Substance; Phase; plasmid DNA; Problem Solving; Procedures; Process; Production; productivity loss; programs; Prophages; Proteins; prototype; public health relevance; Pump; Reaction; Readiness; repaired; research study; Running; Seeds; sensor; Signal Transduction; software development; Stress; System; Technology; Testing; therapeutic vaccine; Toxin; Toxoids; Vaccines; Work